Alexion Pharmaceuticals, Inc.

Alexion Antibody Technologies, Inc.

Katherine S Bowdish

John R McWhirter

Anke Kretz-Rommel

Shana Frederickson

Toshiaki Maruyama

Mark Renshaw

Dayang Wu

Susan Faas McKnight

Jeremy P Springhorn

John Mcwhirter

Ying-Chi Lin

Martha Wild

Susan Faas Mcknight

Hong Xin

Naveen Dakappagari

Maruyama Toshiaki

Shana Fredrickson

Shana Barbas-Frederickson

Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

Rationally designed antibodies

Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion.

Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.

This application provides methods and compositions for modulating and/or depleting CD200 positive cells.

Antibodies to OX-2/CD200 and uses thereof

Small animal models for assessing immunomodulatory effects of compounds are provided.

Polypeptides and antibodies derived from chronic lymphocytic Leukemia cells and uses thereof

The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are useful in studying and treating cancer.

Methods for treating chronic lymphocytic leukemia

Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

Chronic lymphocytic leukemia cell line

Phagemid vectors containing a sequence of features between a Col E1 origin and an f1 origin are useful for display of polypeptides or proteins, including antibody libraries.

Phagemid vectors

Templates that are engineered to contain a predetermined sequence and a hairpin structure are provided by a nested oligonucleotide extension reaction. The engineered template allows Single Primer Amplification (SPA) to amplify a target sequence within the engineered template. In particularly useful embodiments, the target sequences from the engineered templates are cloned into expression vehicles to provide a library of polypeptides or proteins, such as, for example, an antibody library.

Growing community of inventors

Del Mar, CA, United States of America

Katherine S Bowdish